Can we aford to have CLL patients on a therapy for the rest of their lifes?

VJHemOnc has 1608 videos Subscribe Here

Description: At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).
Shared By : VJHemOnc
Posted on : 01/13/16
Added : 4 years ago